Exchange Surveillance
No active ASM or GSM measures on this stock.
Price band ± 20%
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
Kilitch Drugs (India) Limited is an India-based company engaged in pharmaceutical business. The Companys services range from manufacturing to marketing a host of formulations in all dosage forms, such as solid, liquid and parenteral forms. The Company is a manufacturer of antibacterial parenteral formulations. Its products include Carbapenems, Cephalosporins, Aminoglycosides, anti malarials, and other anti-infectives. The Company trades in Eyekare Pharmaceuticals products and is located in Mumbai. On February 28, 2012, the Company discontinued its manufacturing activity at Paonta Sahib. The Company also transferred certain products by entering into a product transfer agreement with Akorn India Pvt. Ltd. (AIPL) by which the right to manufacture certain products by the Company at Mumbai were sold to AIPL.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- New Mumbai, Maharashtra
- CEO & MD
- Mukund P Mehta
- Registrar
- Link Intime India Pvt. Ltd.
- Exchange
- NSE
- ISIN
- INE729D01010
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Kilitch Drugs India Ltd today?
Kilitch Drugs India Ltd (KILITCH) is trading at ₹202.24. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is KILITCH’s P/E ratio versus the sector?
KILITCH trades at a P/E of 20.5. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is KILITCH’s dividend yield?
KILITCH has a dividend yield of 0.00%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is KILITCH’s 52-week high and low?
KILITCH has traded between ₹117.25 and ₹267.9 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Kilitch Drugs India Ltd?
Kilitch Drugs India Ltd has a market capitalisation of ₹669 crore.
▶What is KILITCH’s return on equity?
KILITCH reports a return on equity of 9.5%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.
▶Who are KILITCH’s competitors?
The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is KILITCH’s promoter holding?
Promoters hold 63.77% of KILITCH. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include KILITCH?
Index membership is listed in the Context block on this page, along with the weight KILITCH carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Kilitch Drugs India Ltd a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from KILITCH’s own numbers. The judgement is yours.
KILITCH at a glance
Kilitch Drugs India Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector. Kilitch Drugs India Ltd (KILITCH) last traded at ₹202.24, giving it a market capitalisation of ₹669 crore. The 52-week range is ₹117.25 to ₹267.9, and the price is 56% of the way up that range. It trades at a price-to-earnings ratio of 20.5. Promoters hold 63.77% of the company in the latest shareholding filing.
| Market cap | ₹669 crore |
|---|---|
| P/E | 20.5 |
| ROE | 9.5% |
| ROCE | 11.4% |